A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.
John B. Watkins, PharmD, MPH, BCPS
Advertisement
Articles by John B. Watkins, PharmD, MPH, BCPS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
3
5 Ongoing Clinical Trials in Myeloproliferative Neoplasms
4
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
5